Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
2.320
-0.119 (-4.86%)
May 12, 2025, 4:00 PM - Market closed
Innate Pharma Employees
Innate Pharma had 181 employees as of December 31, 2024. The number of employees increased by 2 or 1.12% compared to the previous year.
Employees
181
Change (1Y)
2
Growth (1Y)
1.12%
Revenue / Employee
$115,090
Profits / Employee
-$282,970
Market Cap
205.98M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
IPHA News
- 6 days ago - Innate Pharma announces conference call and webcast for Q1 2025 business update - Business Wire
- 12 days ago - Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F - Business Wire
- 13 days ago - Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting - Business Wire
- 18 days ago - Innate Pharma Announces €15M Investment by Sanofi - Business Wire
- 19 days ago - Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company - Business Wire
- 26 days ago - Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition - Business Wire
- 26 days ago - Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025 - Business Wire
- 5 weeks ago - Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum - Business Wire